Evidence map›Paper›PMID 34782706›Full record

ArticleScientific reports2021

Methylation profiling reveals novel molecular classes of rhabdomyosarcoma.

Michael R Clay, Anand Patel, Quynh Tran, Dale J Hedges, Ti-Cheng Chang, Elizabeth Stewart, Greg Charville, Cynthia Cline, Michael A Dyer, Brent A Orr

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  5. Review
  6. Review
  7. Rhabdomyosarcoma in children and young adults.Virchows Archiv : an international journal of pathology · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Complete loss ofHGG advances · 2023
    Article
  12. Review
  13. Case Report: Sequential postzygoticFrontiers in genetics · 2023
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michael R Clay *Department of Pathology, University of Colorado Hospital, Anschutz Inpatient Pavilion 1, 12605 East 16th Avenue, Room 3.003, Aurora, CO, 80045, USA. michael.clay@cuanschutz.edu.
Anand Patel *Department of Oncology, St. Jude Children's Research Hospital, Memphis, USA.
Quynh TranDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, MS25038105, USA.
Dale J HedgesCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, USA.
Ti-Cheng ChangCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, USA.
Elizabeth StewartDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, USA.
Greg CharvilleDepartment of Pathology, Stanford Hospital and Clinics, Palo Alto, USA.
Cynthia ClineDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, USA.
Michael A DyerDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, USA.
Brent A Orr *Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, MS25038105, USA. brent.orr@stjude.org.
St. Jude Children's Research Hospital · USStanford Health Care · USUniversity of Colorado Denver · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Novel Therapeutic Approaches for the Treatment of RhabdomyosarcomaR01CA219686 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI DYER, MICHAEL A · 2017 to 2021
$2.0M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA219686
6 · The paper itself

Abstract

Rhabdomyosarcomas (RMS) represent a family of aggressive soft tissue sarcomas that present in both children and adults. Pathologic risk stratification for RMS has been based on histologic subtype, with poor outcomes observed in alveolar rhabdomyosarcoma (ARMS) and the adult-type pleomorphic rhabdomyosarcoma (PRMS) compared to embryonal rhabdomyosarcoma (ERMS). Genomic sequencing studies have expanded the spectrum of RMS, with several new molecularly defined entities, including fusion-driven spindle cell/sclerosing rhabdomyosarcoma (SC/SRMS) and MYOD1-mutant SC/SRMS. Comprehensive genomic analysis has previously defined the mutational and copy number spectrum for the more common ERMS and ARMS and revealed corresponding methylation signatures. Comparatively, less is known about epigenetic correlates for the rare SC/SRMS or PRMS histologic subtypes. Herein, we present exome and RNA sequencing, copy number analysis, and methylation profiling of the largest cohort of molecularly characterized RMS samples to date. In addition to ARMS and ERMS, we identify two novel methylation subtypes, one having SC/SRMS histology and defined by MYOD1 p. L122R mutations and the other matching adult-type PRMS. Selected tumors from adolescent patients grouped with the PRMS methylation class, expanding the age range of these rare tumors. Limited follow-up data suggest that pediatric tumors with MYOD1-mutations are associated with an aggressive clinical course.

Indexed as

Biomarkers, TumorDNA MethylationGene Expression ProfilingGene Expression Regulation, NeoplasticAdolescentAdultAgedChildChild, PreschoolComputational BiologyDiagnosis, DifferentialDisease SusceptibilityDNA Copy Number VariationsFemaleHumansImmunohistochemistryBiomarkers, Tumor

Identifiers

PMID34782706
PMCPMC8592993
OpenAlexW3213571080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.